Login to Your Account


Dogged by price control threats, biopharma fights for innovation

By Karen Pihl-Carey
Analyst

Friday, April 7, 2017

About a year after legislators lambasted Turing Pharmaceuticals’ former CEO, Martin Shkreli, for hiking by 5,000 percent the price of life-saving toxoplasmosis drug Daraprim, a firestorm has pummeled the biopharmaceutical industry.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics